ABSTRACT
Prader-Willi syndrome (PWS) is a genetic disorder produced by a lack of expression of paternally derived genes in the 15q11-13 region. Research has generally focused on its genetic and behavioral expression, but only a few studies have examined epigenetic influences. Prenatal testosterone or the maternal testosterone-to-estradiol ratio (MaTtEr) has been suggested to play an important role in the development of the 'social brain' during pregnancy. Some studies propose the 2D:4D digit ratio of the hand as an indirect MaTtEr measure. The relationship between social performance and MaTtEr has been studied in other neurodevelopmental conditions such as Autism Spectrum Disorder (ASD), but to our best knowledge, it has never been studied in PWS. Therefore, our study aims to clarify the possible existence of a relationship between social performance-as measured using the Social Responsiveness Scale (SRS)-and MaTtEr levels using the 2D:4D ratio. We found that, as a group, PWS individuals have shorter index and ring fingers than the control group, but no significant difference in the 2D:4D ratios. The 2D:4D ratio showed a correlation only with Restricted Interests and Repetitive Behavior Subscale, where a positive correlation only for male individuals with PWS was found. Considering only PWS with previous GH treatment during childhood/adolescence (PWS-GH), index and ring fingers did not show differences in length with the control group, but the 2D:4D ratio was significantly higher in the right or dominant hand compared to controls.
ABSTRACT
ObjectiveTo develop an insight scale for Prader-Willi Syndrome (PWS), a genetically determined neurodevelopmental disorder with different psychopathological and behavioural problems.MethodologyA sample of 36 PWS patients (58.3% women) attended at the Endocrinological Department of the Corporació Sanitària Parc Taulí (Sabadell, Barcelona) was evaluated. Insight was assessed by means of an adapted version of the Scale of Unawareness of Mental Disorder (SUMD), including three general insight dimensions: awareness of having a PWS, awareness of the effects of psychopharmacological medication and awareness of the social consequences, as well as three items that assess awareness of each particular symptom of the disease (obesity/overweight, excessive appetite and excessive food intake).ResultsThe final Scale included six items and demonstrated an adequate internal consistency (Cronbach Alfa of 0.857 for Caregivers and 0.798 for Clinicians) but a high inter-rate variability. External validation using an Analytical-Visual Insight Scale was adequate.ConclusionsThe Adapted version for Prader-Willi patients of the Scale of Unawareness of Mental Disorder (APW-SUD) showed adequate psychometric properties and it is an easy to administer means to assess insight in this population. (AU)
ObjetivoDesarrollar una escala de insight para el síndrome de Prader-Willi (PWS), un trastorno del desarrollo genéticamente determinado, con diferentes problemas psicopatológicos y conductuales.MetodologíaEvaluamos una muestra de 36 PWS (58,3% mujeres), atendidos en el Departamento de Endocrinología de la Corporació Sanitària Parc Taulí (Sabadell, Barcelona). El insight fue valorado mediante una versión adaptada de la Scale of Unawareness of Mental Disorder, incluyendo tres dimensiones generales: conciencia de tener PWS, conciencia de los efectos de la medicación psicofarmacológica, y conciencia de las consecuencias sociales, así como tres ítems que valoran el insight de cada síntoma particular de la enfermedad (obesidad/sobrepeso, excesivo apetito y exceso de ingesta).ResultadosLa escala final incluye seis ítems y ha demostrado una adecuada consistencia interna (alfa de Cronbach de 0,857 para cuidadores y de 0,798 para clínicos), pero una alta variabilidad interobservador. La validación externa usando una escala analítico-visual de insight fue adecuada.ConclusionesLa versión adaptada para pacientes con PWS de la Scale of Unawareness of Mental Disorder muestra adecuadas propiedades psicométricas y es una vía fácil de administrar para evaluar el insight en esta población. (AU)
Subject(s)
Humans , Prader-Willi Syndrome/complications , Prader-Willi Syndrome/diagnosis , Prader-Willi Syndrome/drug therapy , Endocrinology , Mental Disorders , PatientsABSTRACT
Although various studies have investigated symptoms of autism spectrum disorder (ASD) in Prader−Willi syndrome (PWS), little is known about the consequences of these symptoms, especially in psychosocial function. We aimed to explore ASD symptoms in adults with PWS with special attention to psychosocial functionality. This cross-sectional study included 26 adults (15 women) with PWS who attended a reference unit for rare diseases. Participants' primary caregivers completed the Social Responsiveness Scale (SRS), and clinicians assessed multidimensional functioning with the Personal and Social Performance Scale (PSP). Impaired social responsiveness was identified in 20 (76.9%) participants, and manifest to marked difficulties in social functioning were identified in 13 (50%). Participants with impaired social responsiveness (SRS ≥ 60) had significantly worse scores in functionality measured with the PSP (U = 12.5; p = 0.009) and with three of the four PSP main areas. Moreover, scores for the Social Cognition domain of the SRS correlated positively with the Socially useful activities (p < 0.05) and Personal and social relationships (p < 0.01) main areas of the PSP. These results suggest that difficulties in social skills should be assessed in all psychosocial evaluations of patients with PWS.
ABSTRACT
OBJECTIVE: To develop an insight scale for Prader-Willi Syndrome (PWS), a genetically determined neurodevelopmental disorder with different psychopathological and behavioural problems. METHODOLOGY: A sample of 36 PWS patients (58.3% women) attended at the Endocrinological Department of the Corporació Sanitària Parc Taulí (Sabadell, Barcelona) was evaluated. Insight was assessed by means of an adapted version of the Scale of Unawareness of Mental Disorder (SUMD), including three general insight dimensions: awareness of having a PWS, awareness of the effects of psychopharmacological medication and awareness of the social consequences, as well as three items that assess awareness of each particular symptom of the disease (obesity/overweight, excessive appetite and excessive food intake). RESULTS: The final Scale included six items and demonstrated an adequate internal consistency (Cronbach Alfa of 0.857 for Caregivers and 0.798 for Clinicians) but a high inter-rate variability. External validation using an Analytical-Visual Insight Scale was adequate. CONCLUSIONS: The Adapted version for Prader-Willi patients of the Scale of Unawareness of Mental Disorder (APW-SUD) showed adequate psychometric properties and it is an easy to administer means to assess insight in this population.
Subject(s)
Prader-Willi Syndrome , Female , Humans , Male , Prader-Willi Syndrome/complications , Prader-Willi Syndrome/diagnosis , Prader-Willi Syndrome/drug therapyABSTRACT
There are no studies about insight or awareness of illness in patients with Prader-Willi Syndrome (PWS). The objective of this study was to explore the level of awareness of the disorder, of the need for medication, and of the social consequences of the disease, as well as of its main symptoms in PWS. We also aimed to explore relationships between awareness and sociodemographic and clinical characteristics, and to compare all data with a matched sample of patients with psychosis. Insight was assessed by an Adapted version of the Scale of Unawareness of Mental Disorder in a cross-sectional pilot study at a University Hospital. Thirty-six individuals with PWS (58.3% women) were included. Results showed that PWS patients had a good awareness of the illness and of the effects of medication, in contrast to a lack of awareness of illness' social consequences. Awareness of obesity/overweight was excellent, as was the awareness of excessive appetite. Awareness of excessive food intake was only mild. Insight correlated with age and functionality, but not with BMI. PWS patients showed a better insight into the illness but a similar awareness of the effects of the medication and of the social consequences of the disease as compared to schizophrenia-spectrum patients. This profile of insight may have relevant clinical implications.
ABSTRACT
OBJECTIVE: To explore motor praxis in adults with Prader-Willi syndrome (PWS) in comparison with a control group of people with intellectual disability (ID) and to examine the relationship with brain structural measurements. METHOD: Thirty adult participants with PWS and 132 with ID of nongenetic etiology (matched by age, sex, and ID level) were assessed using a comprehensive evaluation of the praxis function, which included pantomime of tool use, imitation of meaningful and meaningless gestures, motor sequencing, and constructional praxis. RESULTS: Results support specific praxis difficulties in PWS, with worse performance in the imitation of motor actions and better performance in constructional praxis than ID peers. Compared with both control groups, PWS showed increased gray matter volume in sensorimotor and subcortical regions. However, we found no obvious association between these alterations and praxis performance. Instead, praxis scores correlated with regional volume measures in distributed apparently normal brain areas. CONCLUSIONS: Our findings are consistent in showing significant impairment in gesture imitation abilities in PWS and, otherwise, further indicate that the visuospatial praxis domain is relatively preserved. Praxis disability in PWS was not associated with a specific, focal alteration of brain anatomy. Altered imitation gestures could, therefore, be a consequence of widespread brain dysfunction. However, the specific contribution of key brain structures (e.g., areas containing mirror neurons) should be more finely tested in future research.
Subject(s)
Mirror Neurons , Prader-Willi Syndrome , Adult , Brain/diagnostic imaging , Gestures , Humans , Imitative Behavior , Prader-Willi Syndrome/complicationsABSTRACT
El síndrome de Prader-Willi es un trastorno genético causado por alteraciones cromosómicas en el segmento 15q11-q13 que incluye sintomatología cognitiva, mental y conductual, así como un fenotipo somático específico. Tanto las alteraciones psicopatológicas más comunes (discapacidad intelectual, obsesiones, impulsividad, comportamientos de tipo autista, autolesiones) como las comorbilidades principales (cuadros afectivos, psicosis, trastorno obsesivo-compulsivo, trastorno del espectro autista) se caracterizan por una gran heterogeneidad, lo que justifica la necesidad de una mayor caracterización de su frecuencia y modo de presentación. Además de sus efectos sobre la composición corporal y la hipotonía, la hormona del crecimiento ha demostrado utilidad en el control conductual, así como algunos psicofármacos. También se han descrito alternativas a nivel experimental que están mostrando resultados alentadores. Un adecuado conocimiento de la psicopatología asociada a este síndrome permitiría mejorar el abordaje clínico, la identificación de los síntomas, la detección de comorbilidades y la instauración de un tratamiento más efectivo
Prader-Willi syndrome is a genetic disorder caused by chromosomal changes in segment 15q11-q13 including cognitive, mental, and behavioral symptoms, as well as a specific physical phenotype. Both the most common psychopathological changes (intellectual disability, obsessions, impulsivity, autism spectrum disorders, self-injuries) and the main psychiatric comorbidities (affective disorders, psychosis, obsessive-compulsive disorder, autism spectrum disorder) are characterized by a great heterogeneity, which warrants the need for better identification of their frequency and clinical signs. In addition to its effects on body compositionand hypotony, growth hormone has been shown to be useful for regulating patient behavior, and psychoactive drugs are also an option. Other alternatives have shown promising results in experimental trials. Adequate understanding of the psychopathology associated to Prader-Willi syndrome would allow for improving clinical approach, symptom identification, detection of comorbidities, and administration of more effective treatments, leading to better clinical outcomes
Subject(s)
Humans , Adolescent , Adult , Prader-Willi Syndrome/complications , Prader-Willi Syndrome/psychology , Comorbidity , Adolescent Behavior , Prader-Willi Syndrome/drug therapy , Psychopathology , Self-Injurious Behavior/complications , Cognition Disorders/complications , Cognition Disorders/psychology , Autism Spectrum Disorder/complications , Compulsive Personality Disorder , Attention Deficit Disorder with HyperactivityABSTRACT
Prader-Willi syndrome is a genetic disorder caused by chromosomal changes in segment 15q11-q13 including cognitive, mental, and behavioral symptoms, as well as a specific physical phenotype. Both the most common psychopathological changes (intellectual disability, obsessions, impulsivity, autism spectrum disorders, self-injuries) and the main psychiatric comorbidities (affective disorders, psychosis, obsessive-compulsive disorder, autism spectrum disorder) are characterized by a great heterogeneity, which warrants the need for better identification of their frequency and clinical signs. In addition to its effects on body compositionand hypotony, growth hormone has been shown to be useful for regulating patient behavior, and psychoactive drugs are also an option. Other alternatives have shown promising results in experimental trials. Adequate understanding of the psychopathology associated to Prader-Willi syndrome would allow for improving clinical approach, symptom identification, detection of comorbidities, and administration of more effective treatments, leading to better clinical outcomes.
Subject(s)
Prader-Willi Syndrome/psychology , Antipsychotic Agents/therapeutic use , Attention Deficit Disorder with Hyperactivity/psychology , Autism Spectrum Disorder/psychology , Child , Cognition Disorders/psychology , Comorbidity , Emotional Regulation , Food Addiction/drug therapy , Food Addiction/psychology , Humans , Intellectual Disability/psychology , Mood Disorders/drug therapy , Mood Disorders/psychology , Obsessive-Compulsive Disorder/drug therapy , Obsessive-Compulsive Disorder/psychology , Phenotype , Prader-Willi Syndrome/drug therapy , Prader-Willi Syndrome/genetics , Self-Injurious Behavior/drug therapy , Self-Injurious Behavior/psychology , Sleep Wake Disorders/psychologyABSTRACT
Warning signals indicating that a food is potentially dangerous may evoke a response that is not limited to the feeling of disgust. We investigated the sequence of brain events in response to visual representations of disgusting food using a dynamic image analysis. Functional MRI was acquired in 30 healthy subjects while they were watching a movie showing disgusting food scenes interspersed with the scenes of appetizing food. Imaging analysis included the identification of the global brain response and the generation of frame-by-frame activation maps at the temporal resolution of 2 s. Robust activations were identified in brain structures conventionally associated with the experience of disgust, but our analysis also captured a variety of other brain elements showing distinct temporal evolutions. The earliest events included transient changes in the orbitofrontal cortex and visual areas, followed by a more durable engagement of the periaqueductal gray, a pivotal element in the mediation of responses to threat. A subsequent core phase was characterized by the activation of subcortical and cortical structures directly concerned not only with the emotional dimension of disgust (e.g., amygdala-hippocampus, insula), but also with the regulation of food intake (e.g., hypothalamus). In a later phase, neural excitement extended to broad cortical areas, the thalamus and cerebellum, and finally to the default mode network that signaled the progressive termination of the evoked response. The response to disgusting food representations is not limited to the emotional domain of disgust, and may sequentially involve a variety of broadly distributed brain networks. Hum Brain Mapp 39:369-380, 2018. © 2017 Wiley Periodicals, Inc.
Subject(s)
Brain/physiology , Motion Perception/physiology , Taste Perception/physiology , Adult , Brain/diagnostic imaging , Brain Mapping , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Motion Pictures , Time Factors , Young AdultABSTRACT
CONTEXT: Prader-Willi syndrome (PWS) is characterized by severe hyperphagia. Brain-derived neurotrophic factor (BDNF) and leptin are reciprocally involved in energy homeostasis. OBJECTIVES: To analyze the role of BDNF and leptin in satiety in genetic subtypes of PWS. DESIGN: Experimental study. SETTING: University hospital. SUBJECTS: 90 adults: 30 PWS patients; 30 age-sex-BMI-matched obese controls; and 30 age-sex-matched lean controls. INTERVENTIONS: Subjects ingested a liquid meal after fasting ≥10 hours. MAIN OUTCOME MEASURES: Leptin and BDNF levels in plasma extracted before ingestion and 30', 60', and 120' after ingestion. Hunger, measured on a 100-point visual analogue scale before ingestion and 60' and 120' after ingestion. RESULTS: Fasting BDNF levels were lower in PWS than in controls (p = 0.05). Postprandially, PWS patients showed only a truncated early peak in BDNF, and their BDNF levels at 60' and 120' were lower compared with lean controls (p<0.05). Leptin was higher in PWS patients than in controls at all time points (p<0.001). PWS patients were hungrier than controls before and after eating. The probability of being hungry was associated with baseline BDNF levels: every 50-unit increment in BDNF decreased the odds of being hungry by 22% (OR: 0.78, 95%CI: 0.65-0.94). In uniparental disomy, the odds of being hungry decreased by 66% (OR: 0.34, 90%CI: 0.13-0.9). Postprandial leptin patterns did no differ among genetic subtypes. CONCLUSIONS: Low baseline BDNF levels and lack of postprandial peak may contribute to persistent hunger after meals. Uniparental disomy is the genetic subtype of PWS least affected by these factors.
ABSTRACT
Los pacientes con esquizofrenia tienen una esperanza de vida menor en comparación con la población general y más riesgo de morir por enfermedad cardiovascular. Estos hechos se han atribuido a la elevada prevalencia de síndrome metabólico. Existen numerosos datos en la literatura médica que profundizan sobre la influencia de la esquizofrenia y del tratamiento antipsicótico en la aparición del síndrome metabólico, así como recomendaciones, guías clínicas y pautas para realizar una prevención, cribado y abordaje adecuados. El objetivo de este trabajo es actualizar la información existente al respecto, comprender los factores etiológicos relacionados, las diferencias entre los distintos antipsicóticos y las recomendaciones para el adecuado tratamiento de los pacientes(AU)
Patients with schizophrenia have a shorter life expectancy and their risk of dying from a cardiovascular disease is higher than the general population. Both facts have been attributed to the raised presence of metabolic syndrome. There is a big amount of scientific publications that deals with the relationship between schizophrenia, antipsychotic treatment, and the development of metabolic syndrome. There is also information about recommendations and clinical guides to achieve an adequate prevention, screening, and treatment of the disease. The aim of this review is to update the current information about this issue and to understand related etiologic factors, differences between antipsychotic drugs, and the current recommendations for patient's care(AU)
Subject(s)
Humans , Metabolic Syndrome/epidemiology , Schizophrenia/complications , Antipsychotic Agents/adverse effects , Risk Factors , Overweight/chemically induced , Hypertension/prevention & controlABSTRACT
UNLABELLED: Atypical antipsychotic-induced hyperprolactinemia can cause important clinical symptoms, particularly in young women and also in men, such as impotence, loss of libido, gynecomastia, anovulation and galactorrhea. METHODS: Observational over one-year follow-up of six patients (four women and two men, mean age of 31.1 years, range 26-37), treated with different atypical antipsychotics in an outpatient psychiatric device, who had clinical complications associated to high prolactin serum levels. All of them were treated with standard doses of cabergoline. RESULTS: Most patients experienced significant clinical improvement after treatment with standard doses of cabergoline (mean dosage 1.08 mg/week), maintained for a mean of 18 month. Normal prolactin levels were achieved after the first months of treatment with cabergoline. No side effects or worsening of psychotic or behavioral symptoms were observed. CONCLUSIONS: Long-term treatment with cabergoline seems to be safe in atypical antipsychotic-treated patients.
Subject(s)
Antipsychotic Agents/adverse effects , Dopamine Agonists/therapeutic use , Ergolines/therapeutic use , Hyperprolactinemia/drug therapy , Adult , Antipsychotic Agents/administration & dosage , Cabergoline , Dopamine Agonists/adverse effects , Ergolines/adverse effects , Female , Follow-Up Studies , Humans , Hyperprolactinemia/chemically induced , Male , Treatment OutcomeABSTRACT
Patients with schizophrenia have a shorter life expectancy and their risk of dying from a cardiovascular disease is higher than the general population. Both facts have been attributed to the raised presence of metabolic syndrome. There is a big amount of scientific publications that deals with the relationship between schizophrenia, antipsychotic treatment, and the development of metabolic syndrome. There is also information about recommendations and clinical guides to achieve an adequate prevention, screening, and treatment of the disease. The aim of this review is to update the current information about this issue and to understand related etiologic factors, differences between antipsychotic drugs, and the current recommendations for patient's care.
Subject(s)
Antipsychotic Agents/adverse effects , Metabolic Syndrome/chemically induced , Schizophrenia/drug therapy , Antipsychotic Agents/therapeutic use , Benzodiazepines/adverse effects , Benzodiazepines/therapeutic use , Blood Glucose/analysis , Cardiovascular Diseases/etiology , Cardiovascular Diseases/mortality , Clozapine/adverse effects , Clozapine/therapeutic use , Comorbidity , Follow-Up Studies , Humans , Hypothalamus/drug effects , Hypothalamus/physiopathology , Incidence , Life Expectancy , Lipid Metabolism/drug effects , Metabolic Syndrome/drug therapy , Metabolic Syndrome/epidemiology , Metabolic Syndrome/physiopathology , Metabolic Syndrome/prevention & control , Obesity, Abdominal/chemically induced , Obesity, Abdominal/epidemiology , Olanzapine , Practice Guidelines as Topic , Schizophrenia/epidemiology , Weight GainABSTRACT
INTRODUCTION: Aripiprazole is a new antipsychotic agent that has proven safe and efficacious in controlled clinical trials. However, few published data on its effectiveness and safety when used in augmentation and combination are available. METHODS: Our study aimed to determine the functional effectiveness and safety of different combinations of aripiprazole with other psychotropics in resistant patients. All acute not selected (15) patients treated with aripiprazole and other psychotropics between February 2005 and May 2007 are included. RESULTS: Mean follow-up 20.4 days. Main diagnosis was schizophrenia (40%) and mean dose of aripiprazole was 25 mg/d. Resistant patients received initially multiple psychotropics (mean 3.3) and their functional status was very low. A significant functional improvement was observed after admission in most (12) of them. Only three patients experienced mild to moderate improvement; another three patients showed extrapyramidal symptoms. No dermatological reactions or adverse effects were observed with lamotrigine association. DISCUSIONS: The combination of aripiprazole with other psychotropics was well tolerated. No significant new adverse reactions were observed. In a short term follow-up, our results show a good tolerability of aripiprazole in combination with other psychotropics of different groups.
Subject(s)
Drug Resistance, Multiple , Drug Resistance , Mental Disorders/drug therapy , Piperazines/therapeutic use , Psychotropic Drugs/therapeutic use , Quinolones/therapeutic use , Adult , Antipsychotic Agents/adverse effects , Antipsychotic Agents/therapeutic use , Aripiprazole , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Obsessive-Compulsive Disorder/drug therapy , Outcome Assessment, Health Care , Personality Disorders/drug therapy , Piperazines/adverse effects , Psychotropic Drugs/adverse effects , Quinolones/adverse effects , Retrospective Studies , Schizophrenia/drug therapy , SpainABSTRACT
Introducción: El trastorno disociativo se ha asociado con la presencia de acontecimientos traumáticos en la infancia y, especialmente, con los abusos sexuales. Igualmente, se han propuesto diversos factores de personalidad que pueden influir en la aparición de este trastorno. Metodología: El presente estudio analiza una muestra de 36 personas diagnosticados de trastorno disociativo (DSM-IV) y atendidos en lasconsultas externas de la Corporació Sanitária Parc Taulí de Sabadell (Barcelona). Se realizó una evaluación de la personalidad mediante el Inventario de Personalidad Millon-II y diferentes mediciones clínicas estandarizadas. Resultados: Se encontraron puntuaciones patológicas en las diversas subescalas en todos los sujetos, pero especialmente una elevación muy significativa de las subescalas de esquizoidia, esquizotipia, histeria, depresión, ansiedad, abuso de alcohol y pensamiento psicótico. o se detectó una presencia significativa de personalidad histriónica en nuestra muestra. Los antecedentes de traumas en la infancia muestran asociación estadísticamente significativa con puntuaciones elevadas en las subescalas de antisocial, narcisista, de esquizoidia y de neurosis depresiva. Sin embargo, la presencia de traumas sexuales específicos en la infancia no se correlaciona con ninguna alteración en las diferentes subescalas. La gravedad de la clínica disociativa se encontraba relacionada con la puntuación en las subescalas de personalidad autodestructiva, de abuso de alcohol, de abuso de drogas, de pensamiento psicótico y de depresión mayor. Conclusiones: En nuestra muestra, la personalidad de los sujetos con síntomas disociativos está más cercana al constructo de personalidad esquizoide y esquizotípica (AU)
Introduction: Dissociative disorders were traditionally associated to traumatic events in the childhood, specially to sexual abuse. Some personality factors were proposed related to these disorders. Methods: The present study analyzes a sample of 36 outpatients suffering from DSM-IV dissociative disorders and treated at the Mental Health Deparment of the Corporació Sanitária Parc Taulí (Barcelona, Spain). We evaluated the personality of the patients with de Personality Inventory Millon-II (Spanish version) and we also evaluated other clinical aspects with standardized measures. Results: The results showed pathological scores in all the patients, but specially in the subscales schizoid, schizotypal, histeriform, depression, anxiety, alcohol abuse and psychotic experiences. Non significant personal history of child trauma shows statistical association with high scores in antisocial, narcissism, schizoid and depressive neurosis subscales. Moreover, the presence of specific sexual trauma in childhood is not related with a specific alteration in any subscale. The severity of dissociative symptoms is related to the scores in the masochism, alcohol buse, drugs abuse, major depression and psychotic thinking subscales. Conclusions: In our sample, the personality of patients with dissociative disorder is more similar to the schizoid or schizotypal personality (AU)
Subject(s)
Humans , Adult , Dissociative Disorders/diagnosis , Personality Inventory , Dissociative Disorders/psychology , Personality Disorders/diagnosis , Socioeconomic Factors , Diagnosis, Dual (Psychiatry)ABSTRACT
Our objective was to identify variables related to the onset of acute posttraumatic stress disorder (PTSD) after a road traffic accident. We evaluated 60 victims of a motor vehicle accident (MVA) in 2004 at 2 months postaccident. Thirty of them had developed PTSD; the other 30 had not developed PTSD. Clinical data, physical injuries, and sociodemographic characteristics were determined in 60 victims. The Davidson Trauma Scale (DTS) and a Structured Clinical Interview for DSM-IV (SCID) were used to evaluate PTSD occurrence. PTSD scores assessed by DTS and SCID at 2 months were significantly and positively associated with female sex, severe physical injuries, perceived social deprivation, and loss of job activity due to the accident. Female sex, severe physical injury, perceived social deprivation, and sick leave were related to the diagnosis of PTSD 2 months after the accident.
Subject(s)
Accidents, Traffic/psychology , Socioeconomic Factors , Stress Disorders, Post-Traumatic/diagnosis , Adolescent , Adult , Case-Control Studies , Comorbidity , Female , Follow-Up Studies , Humans , Injury Severity Score , Male , Mental Disorders/epidemiology , Mental Disorders/psychology , Middle Aged , Personality Assessment , Psychosocial Deprivation , Referral and Consultation , Risk Factors , Sick Leave , Spain , Stress Disorders, Post-Traumatic/epidemiology , Stress Disorders, Post-Traumatic/psychology , Unemployment , Wounds and Injuries/epidemiology , Wounds and Injuries/psychologyABSTRACT
BACKGROUND: Thiopurinic immunomodulators are effective for maintaining symptom remission in Crohn's disease. Little is known, however, about their effect on patients' quality of life or psychological well-being. The present study aimed to determine whether remission induced by thiopurinic immunomodulators returns levels of quality of life and psychological well-being to normal. MATERIALS AND METHODS: A case-control study was performed. Cases were 33 patients with Crohn's disease treated with azathioprine or 6-mercaptopurine and in stable remission for at least 6 months. Sixty-six healthy individuals matched 2:1 by age and sex and 14 patients with active Crohn's disease were included as control groups. Quality of life was evaluated with the Short Form (SF-36) questionnaire, and the respective Hamilton rating scales were used for anxiety and depression. ANOVA with Bonferroni's correction was used for multiple comparisons. RESULTS: SF-36 global scores were 85 in the study group, 85 in healthy controls (P = 1), and 58.6 in patients with active disease (P < 0.001 for the comparison with the other 2 groups). The differences between values were 0 (95% CI -4-4), 26.4 (95% CI 20-32), and 26.4 (95% CI 19-33), respectively. The respective anxiety and depression scores were 6.5, 5.5, and 16.2 and 3.7, 3.3, and 10.9. No significant differences were observed in any of the SF-36 domains between case and control groups, whereas in patients with active disease, all domains were significantly worse. CONCLUSIONS: Thiopurinic immunomodulator-induced remission restores normal levels of quality of life and psychological well-being in Crohn's disease patients.